Safety of proton pump inhibitors and risk of gastric cancers: Review of literature and pathophysiological mechanisms

Expert Opinion on Drug Safety

Volumn 15, Issue 1, 2016, Pages 53-63

  Ko, Yanna ^a   Tang, James ^a   Sanagapalli, Santosh ^a   Kim, Bong Sik Matthew ^a   Leong, Rupert W ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

adverse effects; Barrett's esophagus; cardioesophageal carcinoma; gastric adenocarcinomas; gastric neuroendocrine tumors; Helicobacter pylori infection; proton pump inhibitors

Indexed keywords

PROTON PUMP INHIBITOR; GASTRIN;

ATROPHIC GASTRITIS; BARRETT ESOPHAGUS; CANCER RISK; CARCINOGENESIS; CHRONIC GASTRITIS; DISEASE COURSE; DRUG SAFETY; DYSPLASIA; ENTEROCHROMAFFIN LIKE CELL; GASTRITIS; HUMAN; HYPERGASTRINEMIA; NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; PERNICIOUS ANEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; ADENOCARCINOMA; ANIMAL; BLOOD; COMPLICATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; NEUROENDOCRINE TUMORS; PATHOLOGY; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; DISEASE PROGRESSION; GASTRINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NEUROENDOCRINE TUMORS; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS;

EID: 84955208350     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2016.1118050     Document Type: Review

References (91)

1. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics. Mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Pediatric Drugs. 2013;15 (2):119-131.
2. Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risk of gastric neoplasia and infections. Expert Opin Drug Saf. 2002;1 (1):29-38.
3. Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70 (5):1-11.
4. Shin JM, Munson K, Vagin O, et al. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch. 2009;457 (3):609-622.
5. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 2: clinical efficacy, safety, and economics. Ann Pharmacother. 2005;39:1844-1851.
6. Forgacs I. Overprescribing proton pump inhibitors. BMJ. 2008;33 (6):p. 2.
7. Batuwitage B, Kingham JGC, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83:66-68.
8. Grant K, Al-Adhami N, Tordoff J, et al. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28:189-193.
9. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138:896-904.
10. Targownik LE, Lix LM, Metge CJ. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319-326.
11. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103 (9):2308-2313.
12. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54 (3):234-235.
13. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171 (1):33-38.
14. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: A population-based case-control study. Arch Int Med. 2007;167:950-955.
15. Laheij RJF, Sturkenboom MCJM, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-1960.
16. Shubert ML, Peura DA. Reviews in basic and clinical gastroenterology: control of gastric acid secretion in health and disease. Gastroenterology. 2008;134:1842-1860.
17. Song H, Zhu J, Lu DH. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014; (12):CD010623. doi:10. 1002/ 14651858. CD010623. pub2.
18. Lundell L, Vieth M, Gibson F, et al. Systematic review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015. Accessed on 15 July 2015: doi:10. 1111/apt. 13324.
19. Ahn JS, Eom CS, Jeon CY, et al. Suppressive drugs and gastric cancer: A meta-analysis of observational studies. World J Gastroenterol. 2013;19 (16):2560-2568.
20. Eslami L, Nasseri-Moghaddam S. Metaanalyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med. 2013;16 (8):449-458.
21. Lawrence B, Kidd M, Svejda B, et al. A clinical perspective on gastric neuroendocrine neoplasia. Curr Gastroenterol Rep. 2011;13:101-109.
22. Hwang JH, Rulyak SD, Kimmey MB. American Gastroenterological Association Institute technical review on the management of gastric subepithelial masses. Gastroenterology. 2006;130:2217-2228.
23. Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008;93:1582-1591.
24. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol. 2008;26 (18):3063-3072.
25. Bordi C, Azzoni C, Ferraro G, et al. Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol. 2000;114:419-425.
26. Walsh JW, Richardson CT, Fordtran JS. pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest. 1975;55:462-468.
27. Havu N, Mattsson H, Ekman L, et al. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion. 1990;45:189-195.
28. Graham DY, Genta RM. Long term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep. 2008;10 (6):543-547.
29. Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci. 2007;52:2482-2489.
30. Corleta V, Festa S, Giulioa ED, et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21:3-8.
31. Rindi G, Solcia E. Endocrine hyperplasia and dysplasia in the pathogenesis of gastrointestinal and pancreatic endocrine tumors. Gastroenterol Clin North Am. 2007;36:851-865.
32. Langhans N, Rindi G, Chiu M, et al. Abnormal gastric histology and decreased acid production in cholescytokinin-B/gastrin receptor-deficient mice. Gastroenterology. 1997;112:280-286.
33. Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther. 2012;36:959-971.
34. Jianu CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther. 2012;36 (7):644-649.
35. Dawson R, Manson JMK. Omeprazole in oesophageal reflux disease. Lancet. 2000;356 (9243):1770-1771.
36. Jianu CS, Lange OJ, Viset T, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2012;47:64-67.
37. Haga Y, Nakatsura T, Shibata Y, et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci. 1998;43:253-257.
38. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after lifelong inhibition of gastric secretion. Digestion. 1986;35 (Suppl. 1):42-55.
39. Poynter D, Pick CR, Harcourt RA, et al. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut. 1985;26:1284-1295.
40. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012;36:37-47.
41. Kokkola A, Sjöblom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol. 1998;33 (p):88-92.
42. Stockbrugger RW, Menon GG, Belby JOW, et al. Gastroscopic screening in 80 patients with pernicious anemia. Gut. 1983;24:1141-1147.
43. Mcguican JE, Trudeau WL. Serum gastrin concentration in pernicious anemia. N Engl J Med. 1970;282:358-361.
44. Creutzfeldt W, Lamberts R, Stockmann F, et al. Quantitative studies of gastric endocrine cells in patients receiving long term treatment with omeprazole. Scand. J. Gastroenterol. 1989;24:122-128.
45. Waldum HL, Haugen OA, Isaksen C, et al. Are diffuse gastric carcinomas neuroendocrine tumours (ECL-omas)? Euro J Gastroenterol HEpatol. 1991;3:245-249.
46. Waldum HL, Aase S, Kvtnoi I, et al. Neuroendocrine differentiation in human gastric carcinomas. Cancer. 1998;83:435-444.
47. Fossmark R, Sørdal O, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36:1067-1075.
48. Von Rosenvinge EC, Wank SA, Lim RM. Gastric masses in multiple endocrine neoplasia type I-associated Zollinger-Ellison syndrome. Gastroenterology. 2009;137 (4):1222.
49. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
50. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19 (8):1893-1907.
51. Shin A, Kim J, Park S. Gastric cancer epidemiology in Korea. J Gastric Cancer. 2011;11:135-140.
52. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23:713-739.
53. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735-6740.
54. Posselt G, Backert S, Wessler S. The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal. 2013;11:77.
55. Hansen S, Vollset SE, Derakhshan MH, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut. 2007;56:918-925.
56. Meining A, Riedl B, Stolte M. Features of gastritis predisposing to gastric adenoma and early gastric cancer. J Clin Pathol. 2002;55:770-773.
57. El-Omar EM, Rabkin CS, Gammon MD, et al. 2003. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 124;1193-1201.
58. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut. 2006;55:1217-1221.
59. Xia HH, Kalantar JS, Talley NJ, et al. Antral-type mucosa in the gastric incisura, body, and fundus (antralization): A link between Helicobacter pylori infection and intestinal metaplasia? Am J Gastroenterol. 2000;95:114-121.
60. Lind T, Cederberg C, Ekenved G, et al. EVect of omeprazole-A gastric acid pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut. 1983;24:270-277.
61. Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut. 1998;43 (Suppl):S56-S60.
62. Graham DY, Opekun AR, Yamaoka Y, et al. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther. 2003;17:193-200.
63. Sanduleanu S, Jonkers D, De Bruïne A, et al. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: Increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 2001;15:1163-1175.
64. Sugano K. Premalignant conditions of gastric cancer. J Gastroenterol Hepatol. 2013;28:906-911.
65. Shin VY, Jin HC, Ng EKO, et al. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone promoted gastric cancer growth through prostaglandin E receptor (EP2 and EP4) in vivo and in vitro. Cancer Sci. 2011;102:926-933.
66. Lewis SJ, Young G, O'Keefe SJD. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. Aliment Pharmacol Ther. 1996;10:557-561.
67. Bektas M, Saraç N, Çetinkaya H, et al. Effects of Helicobacter pylori infection and long-term proton pump inhibitor use on enterochromaffin-like cells. Ann Gastroenterol. 2012;25 (12):123-127.
68. Eissele R, Brunner GORIK, Simon B, et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology. 1997;1997:707-717.
69. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018-1022.
70. Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: A population-based cohort study. Br J Cancer. 2009;100:1503-1507.
71. Hawker PC, Muscroft TJ, Keighley MR. Gastric cancer after cimetidine in patient with two negative pre-treatment biopsies. Lancet. 1980;1:709-710.
72. Mullen PW. Gastric cancer in patients who have taken cimetidine. Lancet. 1979;1:1406.
73. Taylor TV, Lee D, Howatson AG, et al. Gastric cancer in patients who have taken cimetidine. Lancet. 1979;1:1135-1136.
74. Raghunath AS, O'Morain C, McLoughlin RC. Review article: The long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22:55-63.
75. Malfertheiner P, Megraud F, O'Morain C. et al. 2006. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report 2005.
76. Deans C, Yeo MSW, Soe MY, et al. Cancer of the gastric cardia is rising in incidence in an Asian Population and is associated with adverse outcome. World J Surg. 2011;35:617-624.
77. Anderson WF, Camargo MC, Fraumeni JF Jr, et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA. 2010;303:1723-1728.
78. Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: A meta-analysis. Gastrointest Endosc. 2008;67:394-398.
79. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
80. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004;99:1877-1883.
81. Cooper BT, Chapman W, Neumann CS, et al. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitor up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther. 2006;23:727-733.
82. Romero Y. Do PPIs diminish Barrett's esophagus length or cancer risk? Nat Clin Pract Gastroenterol Hepatol. 2006;3:658-659.
83. McCarthy D. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol. 2010;26:624-631.
84. Harris JC, Clarke PA, Awan A, et al. An antiapoptotic role for gastrin and the gastrin/ CCK-2 receptor in Barrett's esophagus. Cancer Res. 2004;64:1915-1919.
85. Haigh CR, Attwood S, Thompson DG, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology. 2003;124:615-625.
86. Ferrand A, Wang T. Gastrin and cancer: A review. Cancer Lett. 2006;238:15-29.
87. Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res. 2004;10:4784-4792.
88. Chueca E, Lanas A, Piazuelo E. Role of gastrin-peptides in Barrett's and colorectal carcinogenesis. World J Gastroenterol. 2012;18:6560-6570.
89. Kaur BS, Khamnehei N, Iravani M, et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology. 2002;123:60-67.
90. Alsalahi O, Dobrian AD. Proton pump inhibitors: The culprit for Barrett's esophagus? Front Oncol. 2014;4:373.
91. Wang JS, Varro A, Lightdale CJ, et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol. 2010;105:1039-1045.